Toxicology and risk assessment of coumarin: Focus on human data

Molecular Nutrition and Food Research

Volumn 54, Issue 2, 2010, Pages 228-239

  Abraham, Klaus ^a   Wöhrlin, Friederike ^a   Lindtner, Oliver ^a   Heinemeyer, Gerhard ^a   Lampen, Alfonso ^a  

^a FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

Author keywords

Coumarin; Exposure; Humans; Risk assessment; Toxicology

Indexed keywords

COUMARIN; COUMARIN DERIVATIVE; FLAVORING AGENT;

ANIMAL; BIOTRANSFORMATION; CHEMICALLY INDUCED DISORDER; CHEMISTRY; EDEMA; GENETICS; HUMAN; LIVER TUMOR; LYMPHEDEMA; MEDICINAL PLANT; PATHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT; SPECIES DIFFERENCE; STANDARD; TOXIC HEPATITIS; TOXICITY TESTING; VEIN INSUFFICIENCY;

ANIMALS; BIOTRANSFORMATION; COUMARINS; DRUG-INDUCED LIVER INJURY; EDEMA; FLAVORING AGENTS; HUMANS; LIVER NEOPLASMS; LYMPHEDEMA; PLANTS, MEDICINAL; RISK ASSESSMENT; SPECIES SPECIFICITY; TOXICITY TESTS; VENOUS INSUFFICIENCY;

ANIMALIA; CINNAMOMUM VERUM; SENNA;

EID: 76749156320     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.200900281     Document Type: Review

References (53)

1. Egan, D., O'Kennedy, R., Moran, E., Cox, D. et al., The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. Drug Metab. Rev. 1990; 22, 503-529.
2. Hazleton, L. W., Tusing, T. W., Zeitlin, B. R., Thiessen, R., Murer, H. K., Toxicity of coumarin. J. Pharmacol. Exp. Ther. 1956, 118, 348-358.
3. Lake, B. G., Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment. Food Chem. Toxicol. 1999, 37, 423-453.
4. EFSA, Opinion of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in Contacts with Food (AFC) on a request from the Commission related to Coumarin; adopted on 6 October 2004, EFSA J. 2004, 104, 1-36. Includes in the Appendix also the previous opinions of the Scientific Committee on Food (SCF) of 1994 and 1999.
5. BfR, High daily intakes of cinnamon: Health risk cannot be ruled out. Health Assessment No. 044/2006, 2006.
6. Sproll, C., Ruge, W., Andlauer, C., Godelmann, R., Lachenmeier, D. W., HPLC analysis and safety assessment of coumarin in foods. Food Chem. 2008, 109, 462-469.
7. EU Food Law, Cinnamon flavoured cereal recalled over coumarin levels. EU Food Law 2006, November 10, 10-11.
8. Felter, S. P., Vassallo, J. D., Carlton, B. D., Daston, G. P., A safety assessment of coumarin taking into account species-specificity of toxicokinetics. Food Chem. Toxicol. 2006, 44, 462-475.
9. Edwards, A. J., Price, R. J., Renwick, A. B., Lake, B. G., Lack of effect of coumarin on unscheduled DNA synthesis in the in vivo rat hepatocyte DNA Repair Assay. Food Chem. Toxicol. 2000, 38, 403-409.
10. Api, A. M., Lack of effect of coumarin on the formation of micronuclei in an in vivo mouse micronucleus assay. Food Chem. Toxicol. 2001, 39, 837-841.
11. Swenberg, J. A., Covalent binding index study on coumarin, Report of Laboratory of Molecular Carcinogenesis and Mutagenesis, University of North Carolina, Chapel Hull, NC 27599, USA. April 2003, Submitted by European Flavour and Flagrance Association (EFFA), Square Marie-Louise, 49, B-1000, Brussels.
12. Hagan, E. C., Hansen, W. H., Fitzhugh, O. G., Jenner, P. M. et al., Food flavourings and compounds of related structure. II. Subacute and chronic toxicity. Food Cosmet. Toxicol. 1967, 5, 141-157.
13. Pearce, R., Greenway, D., Parkinson, A., Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. Arch. Biochem. Biophys. 1992, 298, 211-225.
14. Vassallo, J. D., Hicks, S. M., Daston, G. P., Lehman-McKeeman, L. D., Metabolic detoxification determines species differences in coumarin-induced hepatotoxicity. Toxicol. Sci. 2004, 80, 249-257
15. Marshall, M. E., Mohler, J. L., Edmonds, K., Williams, B. et al., An updated review of the clinical development of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin. J. Cancer Res. Clin. Oncol. 1994, 120, S39-42.
16. Cox, D., O'Kennedy, R., Thornes, R. D., The rarity of liver toxicity in patients treated with coumarin (1,2-benzopyrone). Hum. Toxicol. 1989, 8, 501-506.
17. WHO, Coumarin: a strong association with hepatotoxicity. WHO Drug Information 1995, 9, 159.
18. Andrejak, M., Gersberg, M., Sgro, C., Decocq, G. et al., French pharmacovigilance survey evaluating the hepatic toxicity of coumarin. Pharmacoepidemiol. Drug. Saf. 1998, 7, S45-S50.
19. Mohler, J. L., Gomella, L. G., Crawford, E. D., Glode, L. M. et al., Phase II evaluation of coumarin (1,2-benzopyrone) in metastatic prostatic carcinoma. Prostate 1992, 20, 123-131.
20. Loprinzi, C. L., Kugler, J. W., Sloan, J. A., Rooke, T. W. et al., Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. N. Engl. J. Med. 1999, 340, 346-350.
21. Burian, M., Freudenstein, J., Tegtmeier, M., Naser-Hijazi, B. et al., Single copy of variant CYP2A6 alleles does not confer susceptibility to liver dysfunction in patients treated with coumarin. Int. J. Clin. Pharmacol. Ther. 2003, 41, 141-147.
22. Schmeck-Lindenau, H. J., Naser-Hijazi, B., Becker, E. W., Henneicke-von Zepelin, H. H., Schnitker, J., Safety aspects of a coumarin-troxerutin combination regarding liver function in a double-blind placebo-controlled study. Int. J. Clin. Pharmacol. Ther. 2003, 41, 193-199.
23. Vanscheidt, W., Rabe, E., Naser-Hijazi, B., Ramelet, A. A. et al., The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa, 2002, 31, 185-190.
24. Adam, B. S., Pentz, R., Siegers, C. P., Strubelt, O., Tegtmeier, M., Troxerutin protects the isolated perfused rat liver from a possible lipid peroxidation by coumarin. Phytomedicine 2005, 12, 52-61.
25. Bergmann, K., Sachverständigengutachten zur Beurteilung von Cumarin in Arzneimitteln in Bezug auf lebertoxische Wirkung beim Menschen, Rheinische Friedrich-Wilhelms-Universität Bonn. 1999, Original report written in German available from the BfArM, Bonn.
26. Abraham, K., Zimt und Cumarin: eine Klarstellung aus wissenschaftlich-behördlicher Sicht. Dtsch. Lebensmittel-Rundschau 2007, 103, 480-487.
27. EFSA, Scientific Opinion of the Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact with Food on a request from the European Commission on Coumarin in flavourings and other food ingredients with flavouring properties. EFSA J. 2008, 793, 1-15.
28. Pelkonen, O., Rautio, A., Raunio, H., Pasanen, M., CYP2A6: a human coumarin 7-hydroxylase. Toxicology. 2000, 144, 139-147.
29. Zhang, Q. Y., Gu, J., Su, T., Cui, H. et al., Generation and characterization of a transgenic mouse model with hepatic expression of human CYP2A6. Biochem. Biophys. Res. Commun. 2005, 338, 318-324.
30. Ritschel, W. A., Brady, M. E., Tan, H. S., First-pass effect of coumarin in man. Int. J. Clin. Pharmacol. Biopharm. 1979, 17, 99-103.
31. Rautio, A., Kraul, H., Kojo, A., Salmela, E., Pelkonen, O., Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics 1992, 2, 227-233.
32. Sharifi, S., Pharmakokinetische Untersuchungen von Cumarin und seinen Metaboliten nach oraler und intravenöser Applikation bei gesunden Probanden. PhD thesis, University of Göttingen 1990.
33. Sharifi, S., Lotterer, E., Michaelis, H. C., Bircher, J., Pharmacokinetics of coumarin and its metabolites. Preliminary results in three volunteers. J. Ir. Coll. Physicians Surg. 1993, 22, 29-32.
34. Meineke, I., Desel, H., Kahl, R., Kahl, G. F., Gundert-Remy, U., Determination of 2-hydroxyphenylacetic acid (2HPAA) in urine after oral and parenteral administration of coumarin by gas-liquid chromatography with flame-ionization detection. J. Pharm. Biomed. Anal. 1998, 17, 487-492.
35. Shilling, W. H., Crampton, R. F., Longland, R. C., Metabolism of coumarin in man. Nature 1969, 221, 664-665.
36. Hadidi, H., Zahlsen, K., Idlem, J. R., Cholerton, S. A., Single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. Food Chem. Toxicol. 1997, 35, 903-907.
37. Mizutani, T., PM frequencies of major CYPs in Asians and Caucasians. Drug Metab. Rev. 2003, 35, 99-106.
38. Rautio, A., Polymorphic CYP2A6 and its clinical and toxicological significance. Pharmacogenomics J. 2003, 3, 5-7.
39. Peamkrasatam, S., Sriwatanakul, K., Kiyotani, K., Fujieda, M. et al., In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais. Drug Metab. Pharmacokinet. 2006, 21, 475-484.
40. Rietjens, I. M., Boersma, M. G., Zaleska, M., Punt, A., Differences in simulated liver concentrations of toxic coumarin metabolites in rats and different human populations evaluated through physiologically based biokinetic (PBBK) modeling. Toxicol. In Vitro 2008, 22, 1890-1901.
41. Carlton, B. D., Aubrun, J.-C., Simon, G. S., Effects of coumarin following perinatal and chronic exposure in Sprague-Dawley rats and CD-1 rats. Fundam. Appl. Toxicol. 1996, 30, 145-151.
42. Sotaniemi, E. A., Rautio, A., Bäckstrom, M., Arvela, P., Pelkonen, O., CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. Br. J. Clin. Pharmacol. 1995, 39, 71-76.
43. Pasanen, M., Rannala, Z., Tooming, A., Sotaniemi, E. A. et al., Hepatitis A impairs the function of human hepatic CYP2A6 in vivo. Toxicology 1997, 123, 177-184.
44. Uetrecht, J., Idiosyncratic Drug Reactions: Past, Present, and Future. Chem. Res. Toxicol. 2008, 21, 84-92.
45. Rychlik, M., Quantification of free coumarin and its liberation from glucosylated precursors by stable isotope dilution assays based on liquid chromatography-tandem mass spectrometric detection. J. Agric. Food. Chem. 2008, 56, 796-801.
46. WHO (World Health Organization) 1999, Cortex Cinnamomi. WHO monographs on selected medicinal plants, Volume 1, Geneva, 1999, pp. 96-104.
47. Miller, K. G., Poole, C. F., Chichila, T. M. P., Solvent-assisted supercritical fluid extraction for the isolation of semivolatile flavor compounds from cinnamons of commerce and their separation by series-coupled column gas chromatography. J. High. Resol. Chromatogr. 1995, 18, 461-471.
48. Weber, G., Zimt-Warenkunde und Markt. Dtsch. Lebensmittel-Rundschau 2007, 103, 492-493.
49. Banasiak, U., Heseker, H., Sieke, C., Sommerfeld, C., Vohmann, C., Abschätzung der Aufnahme von Pflanzenschutzmittel-Rückständen in der Nahrung mit neuen Verzehrsmengen für Kinder. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2005, 1, 84-98.
50. Floc'h, F., Mauger, F., Desmus, J. R., Gard, A. et al., Coumarin in plants and fruits: implication in perfumery. Perfumer Flavorist 2002, 27, 332-336.
51. Yourick, J. J., Bronaugh, R. L., Percutaneous absorption and metabolism of Coumarin in human and rat skin. J. Appl. Toxicol. 1997, 17, 153-158.
52. SKLM (Senatskommission zur Beurteilung der gesundheitlichen Unbedenklichkeit von Lebensmitteln), Natural Constituents of Foods: Assessing the toxicity of substances administered as pure compounds compared to their ingestion as inherent food components. Statement of the DFG-Senate commission on Food Safety. 2006.
53. Renwick, A. G., Data-derived safety factors for the evaluation of food additives and environmental contaminants. Food Addit. Contam. 1993, 10, 275-305.